PDEs as drug targets for CNS immune disorders

Current Opinion in Investigational Drugs

Volumn 9, Issue 7, 2008, Pages 744-753

  Hebb, A L O ^a   Robertson, H A ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Cytokine; Depression; Multiple sclerosis; Parkinson's disease; Schizophrenia; T cell

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIINFLAMMATORY AGENT; APOMORPHINE; BROMOCRIPTINE; CYCLIC AMP; CYCLIC GMP; DOPAMINE; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LEVODOPA; MESSENGER RNA; NORADRENALIN; PHOSPHODIESTERASE; PHOSPHODIESTERASE 7A1; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PHOSPHODIESTERASE IXA; PHOSPHODIESTERASE VII INHIBITOR; PHOSPHODIESTERASE XIA; PHYTOHEMAGGLUTININ; ROLIPRAM; SEROTONIN; SPLEEN EXONUCLEASE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL TISSUE; ANOREXIA; CD4+ T LYMPHOCYTE; CELL FUNCTION; CENTRAL NERVOUS SYSTEM DISEASE; DEPRESSION; DRUG TARGETING; ENZYME BINDING; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOLOGY; INFLAMMATORY CELL; MAJOR DEPRESSION; MELANCHOLIA; MENTAL DISEASE; MOUSE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NAUSEA; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOMOTOR RETARDATION; RAT; REVIEW; SCHIZOPHRENIA; SECOND MESSENGER; SIGNAL TRANSDUCTION; SLEEP DISORDER; T LYMPHOCYTE ACTIVATION; VOMITING; WEIGHT REDUCTION;

ANIMALS; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; ENZYME INHIBITORS; HUMANS; NEUROTRANSMITTER AGENTS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 46749116908     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (148)

1. Beavo JA: Cyclic nucleotide phosphodiesterase: Functional implications of multiple isoforms. Physiol Rev (1995) 75(4):725-748.
2. Conti M, Jin SL: The molecular biology of cyclic nucleotide phosphodiesterases. In: Progress in Nucleic Acid Research and Molecular Biology. Moldave K (Ed), Academic Press, San Diego, CA, USA (1999) 63:1-38.
3. Giembycz MA, Smith SJ: Phosphodiesterase 7A: A new therapeutic target for alleviating chronic inflammation? Curr Pharm Des (2006) 12(25):3207-3220.
4. Lugnier C: Cyclic nucleotide phosphodiesterase (PDE) superfamily: A new target for the development of specific therapeutic agents. Pharmacol Ther (2006) 109(3):366-398.
5. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, McCann SM, Licinio J: Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA (2006) 103(41):15124-15129.
6. Jones NA, Leport M, Holand T, Vos T, Morgan M, Fink M, Pruniaux MP, Berthelier C, O'Connor BJ, Bertrand C, Page CP: Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. Pulm Pharmacol Ther (2007) 20(1):60-68.
7. Tzeng SF, Hsiao HY, Mak OT: Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy (2005) 4(3):335-340.
8. Strous RD, Shoenfeld Y: To smell the immune system: Olfaction, autoimmunity and brain involvement. Autoimmun Rev (2006) 6(1):54-60.
9. Perry VH, Andersson PB, Gordon S: Macrophages and inflammation in the central nervous system. Trends Neurosci (1993) 16(7):268-273.
10. Besedovsky H, Sorkin E, Felix D, Haas H: Hypothalamic changes during the immune response. Eur J Immunol (1977) 7(5):323-325.
11. Anisman H, Zalcman S, Zacharko RM: The impact of stressors on immune and central neurotransmitter activity: Bidirectional communication. Rev Neurosci (1993) 4(2):147-180.
12. Skaper SD: The brain as a target for inflammatory processes and neuroprotective strategies. Ann NY Acad Sci (2007) 1122:23-34.
13. Brooks WH, Cross RJ, Roszman TL, Markesbery WR: Neuroimmunomodulation: Neuroanatomical basis for impairment and facilitation. Ann Neurol (1982) 12(1):56-61.
14. Cross RJ, Markesbery WR, Brooks WH, Roszman TL: Hypothalamic-immune interactions. I. The acute effect of anterior hypothalamic lesions on the immune response. Brain Res (1980) 196(1):79-87.
15. Cross RJ, Markesbery WR, Brooks WH, Roszman TL: Hypothalamic-immune interactions: Neuromodulation of natural killer activity by lesioning the anterior hypothalamus. Immunology (1984) 51(2):399-405.
16. Koff WC, Fann AV, Dunegan MA, Lachman LB: Catecholamine-induced suppression of interleukin-1 production. Lymphokine Res (1986) 5(4):239-247.
17. Katayama M, Kobayashi S, Kuramoto N, Yokoyama MM: Effects of hypothalamic lesions on lymphocyte subsets in mice. Ann NY Acad Sci (1987) 496:366-376.
18. Roszman TL, Cross RJ, Brooks WH, Markesbery WR: Hypothalamic-immune interactions II. The effect of hypothalamic lesions on the ability of adherent spleen cells to limit lymphocyte blastogenesis. Immunology (1982) 45(4):737-742.
19. Besedovsky H, Sorkin E, Felix D, Haas H: Hypothalamic changes during the immune response. Eur J Immunol (1977) 7(5):323-325.
20. Carlson JN, Stanley SD, Hinds PA: Changes in d-amphetamine elicited rotational behavior in rats exposed to uncontrollable footshock stress. Pharmacol Biochem Behav (1987) 26(1):17-21.
21. Zalcman S, Shanks N, Anisman H: Time dependent variations of central norepinephrine and dopamine following antigen administration. Brain Res (1991) 557(1-2):69-76.
22. Dunn, AJ: Role of cytokines in infection-induced stress. In: Corticotropin Releasing Factor and Cytokines: Role in the Stress Response (Annals of the New York Academy of Sciences). Tache Y, Rivier C (Eds), New York Academy of Sciences, New York, NY, USA (1993) 697:189-202.
23. Mohankumar PS, Thyagarajan S, Quadri SK: Interleukin-1β increases 5-hydroxyindoleacetic acid release in the hypothalamus in vivo. Brain Res Bull (1993) 31(6):745-748.
24. Rivier C: Effect of peripheral and central cytokines on the hypothalamic-pituitary-adrenal axis of the rat. Ann NY Acad Sci (1993) 697:97-105.
25. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, Yagi G, Kato R, Asai M: Interleukin-1β augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci (1993) 13(8):3574-3581.
26. Terao A, Oikawa M, Saito M: Cytokine-induced change in hypothalamic norepinephrine turnover: Involvement of corticotropin-releasing hormone and prostaglandins. Brain Res (1993) 622(1-2):257-261.
27. Wan W, Janz L, Vriend CY, Sorensen CM, Greenberg AH, Nance DW: Differential induction of c-Fos immunoreactivity in hypothalamus and brain stem nuclei following central and peripheral administration of endotoxin. Brain Res Bull (1993) 32(6):581-587.
28. Vig M, George A, Sen R, Durdik J, Rath S, Bal V: Commitment of activated T cells to secondary responsiveness is enhanced by signals mediated by cAMP-dependent protein kinase A-I. Mol Pharmacol (2002) 62(6):1471-1481.
29. Kanda N, Watanabe S: Regulatory roles of adenylate cyclase and cyclic nucleotide phosphodiesterases 1 and 4 in interleukin-13 production by activated human T cells. Biochem Pharmacol (2001) 62(4):495-507.
30. Arp J, Kirchhof MG, Baroja ML, Nazarian SH, Chau TA, Strathdee CA, Ball EH, Madrenas J: Regulation of T-cell activation by phosphodiesterase 4B2 requires its dynamic redistribution during immunological synapse formation. Mol Cell Biol (2003) 23(22):8042-8057.
31. Crocker IC, Church MK, Ohia SE, Townley RG: Beclomethasone decreases elevations in phosphodiesterase activity in human T lymphocytes. Int Arch Allergy Immunol (2000) 121(2):151-160.
32. Bechoua S, Dubois M, Dominguez Z, Goncalves A, Némoz G, Lagarde M, Prigent AF: Protective effect of docosahexaenoic acid against hydrogen peroxide-induced oxidative stress in human lymphocytes. Biochem Pharmacol (1999) 57(9):1021-1030.
33. Down G, Siederer S, Lim S, Daley-Yates P: Clinical pharmacology of cilomilast. Clin Pharmacokinet (2006) 45(3):217-233.
34. Jones NA, Boswell-Smith V, Lever R, Page CP: The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro. Pulm Pharmacol Ther (2005) 18(2):93-101.
35. Schubert P, Morino T, Miyazaki H, Ogata T, Nakamura Y, Marchini C, Ferroni S: Cascading glia reactions: A common pathomechanism and its differentiated control by cyclic nucleotide signaling. Ann NY Acad Sci (2000) 903:24-33.
36. Zhang B, Yang L, Konishi Y, Maeda N, Sakanaka M, Tanaka J: Suppressive effects of phosphodiesterase type IV inhibitors on rat cultured microglial cells: Comparison with other types of cAMP-elevating agents. Neuropharmacology (2002) 42(2):262-269.
37. Buttini M, Mir A, Appel K, Wiederhold KH, Limonta S, Gebicke-Haerter PJ, Boddeke HW: Lipopolysaccharide induces expression of tumour necrosis factor α in rat brain: Inhibition by methylprednisolone and by rolipram. Br J Pharmacol (1997) 122(7):1483-1489.
38. Suzumura A, Ito A, Yoshikawa M, Sawada M: Ibudilast suppresses TNFα production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS. Brain Res (1999) 837 (1-2):203-212.
39. Dinter H, Tse J, Halks-Miller M, Asarnow D, Onuffer J, Faulds D, Mitrovic B, Kirsch G, Laurent H, Esperling P, Seidelmann D et al: The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J Neuroimmunol (2000) 108(1-2):136-146.
40. Reyes-Irisarri E, Sánchez AJ, García-Merino JA, Mengod G: Selective induction of cAMP phosphodiesterase PDE4B2 expression in experimental autoimmune encephalomyelitis. J Neuropathol Exp Neurol (2007) 66(10):923-931.
41. Bielekova B, Lincoln A, McFarland H, Martin R: Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol (2000) 164(2):1117-1124.
42. Lauer CJ, Schreiber W, Holsboer F, Krieg JC: In quest of identifying vulnerability markers for psychiatric disorders by all-night polysomnography. Arc Gen Psychiat (1995) 52(2):145-153.
43. American Psychiatric Association: DSM-IV: Diagnostic and Statistical Manual of Mental Disorders. 4th Edition, American Psychiatric Publishing, Washington, DC, USA (1994).
44. Darko DF, Irwin MR, Risch SC, Gillin JC: Plasma β-endorphin and natural killer cell activity in major depression: A preliminary study. Psychiatry Res (1992) 43(2):111-119.
45. Maes M, Stevens WJ, Declerck LS, Bridts CH, Peeters D, Schotte C, Cosyns P: Significantly increased expression of T-cell activation markers (interleukin-2 and HLA-DR) in depression: Further evidence for an inflammatory process during that illness. Prog Neuropsychopharmacol Biol Psychiatry (1993) 17(2):241-255.
46. Maes M, Smith R, Scharpe S: The monocyte-T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology (1995) 20(2):111-116.
47. Morikawa K, Oseko F, Morikawa S: Immunosuppressive activity of bromocriptine on human T lymphocyte function in vitro. Clin Exp Immun (1994) 95(3):514-518.
48. Mouret J, Lemoine P, Minuit M-P: Polygraphic, clinical and therapeutic markers of dopamine dependent depressions. C R Acad Sci III (1987) 305(8):301-306.
49. Brown AS, Gershon S: Dopamine and depression. J Neural Trans Gen Sect (1993) 91(2-3):75-109.
50. Dougherty DD, Sortwell CE, Sagen J: Pharmacologic specificity of antidepressive activity by monoaminergic neural transplants. Psychopharmacology (1995) 118(1):10-18.
51. D'Sa C, Eisch AJ, Bolger GB, Duman RS: Differential expression and regulation of the cAMP-selective phosphodiesterase type 4A splice variants in rat brain by chronic antidepressant administration. Eur J Neurosci (2005) 22(6):1463-1475.
52. Zhang HT, Huang Y, Jin SL, Frith SA, Suvarna N, Conti M, O'Donnell JM: Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme. Neuropsychopharmacology (2002) 27(4):587-595. • This paper is of particular interest as it reports that PDE4D plays a fundamental role in depression. The antidepressant-like effects induced by desipramine and fluoxetine were similar among wild-type and PDE4D-deficient mice, while the efficacy of rolipram was absent in PDE4D-deficient mice, suggesting that PDE4D plays a critical role in cAMP signaling that is directly linked to mood.
53. Jeon YH, Heo YS, Kim CM, Hyun YL, Lee TG, Ro S, Cho JM: Phosphodiesterase: Overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci (2005) 62(11):1198-1220.
54. Zhu J, Mix E, Winblad B: The antidepressant and anti-inflammatory effects of rolipram in the central nervous system. CNS Drug Rev (2001) 7(4):387-398.
55. Smith SJ, Brookes-Fazakerley S, Donnelly LE, Barnes PJ, Barnette MS, Giembycz MA: Ubiquitous expression of phosphodiesterase 7A in human proinflammatory and immune cells. Am J Physiol Lung Cell Mol Physiol (2003) 284(2):L279-L289.
56. Nakata A, Ogawa K, Sasaki T, Koyama N, Wada K, Kotera J, Kikkawa H, Omori K, Kaminuma O: Potential role of phosphodiesterase 7 in human T cell function: Comparative effects of two phosphodiesterase inhibitors. Clin Exp Immunol (2002) 128(3):460-466.
57. Lee R, Wolda S, Moon E, Esselstyn J, Hertel C, Lerner A: PDE7A is expressed in human B-lymphocytes and is up-regulated by elevation of intracellular cAMP. Cell Signal (2002) 14(3):277-284.
58. Glavas NA, Ostenson C, Schaefer JB, Vasta V, Beavo JA: T cell activation up-regulates cyclic nucleotide phosphodiesterases 8A1 and 7A3. Proc Natl Acad Sci USA (2001) 98(11):6319-6324.
59. Miró X, Pérez-Torres S, Palacios JM, Puigdomènech P, Mengod G: Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs. Synapse (2001) 40(3):201-214.
60. Pérez-Torres S, Cortés R, Tolnay M, Probst A, Palacios JM, Mengod G: Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization. Exp Neurol (2003) 182(2):322-334.
61. Reyes-Irisarri E, Pérez-Torres S, Mengod G: Neuronal expression of cAMP-specific phosphodiesterase 7B mRNA in the rat brain. Neuroscience (2005) 132(4):1173-1185.
62. Cho CH, Cho DH, Seo MR, Juhnn YS: Differential changes in the expression of cyclic nucleotide phosphodiesterase isoforms in rat brains by chronic treatment with electroconvulsive shock. Exp Mol Med (2000) 32(3):110-114.
63. Wong ML, Whelan F, Deloukas P, Whittaker P, Delgado M, Cantor RM, McCann SM, Licinio J: Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proc Natl Acad Sci USA (2006) 103(41):15124-15129.
64. Lotharius J, Brundin P: Pathogenesis of Parkinson's disease: Dopamine, vesicles and α-synuclein. Nat Rev Neurosci (2002) 3(12):932-942.
65. Agid Y, Javoy-Agid F: Peptides and Parkinson's disease. Trends Neurosci (1985) 8(1):30-35.
66. Piolti R, Appollonio I, Cocco E, Ferrarese C, Frattola L, Rovati L, Panerai AE: Treatment of Parkinson's disease with proglumide, a CCK antagonist. Neurology (1991) 41(5):749-750.
67. Narabayashi H: The neural mechanisms and progressive nature of symptoms of Parkinson's disease - based on clinical, neurophysiological and morphological studies. J Neural Trans (1995) 10(1):63-75.
68. White RF, Au R, Durso R, Moss MB: Neuropsychological function in Parkinson's disease. In: Clinical Syndromes in Adult Neuropsychology: The Practitioner's Handbook. White RF (Ed) Elsevier, Amsterdam, The Netherlands (1992):253-286.
69. Riley DE, Lang AE: The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology (1993) 43(8):1459-1464.
70. Lezak MD: Neuropsychological Assessment. 2nd Edition, Oxford University Press, New York, NY, USA (1983).
71. Menza M, Forman N, Sage J, Cody R: Psychiatric symptoms in Parkinson's disease: A comparison between patients with and without "on-off" symptoms. Biol Psychiatry (1993) 33(8-9):682-684.
72. Siemers ER, Shekhar A, Quaid K, Dickson H: Anxiety and motor performance in Parkinson's disease. Movement Disord (1993) 8(4):501-506.
73. Vázquez A, Jiménez-Jiménez FJ, García-Ruiz P, García-Urra D: Panic attacks in Parkinson's disease: A long-term complication of levodopa therapy. Acta Neurol Scand (1993) 87(1):14-18.
74. Maricle RA, Nutt JG, Carter JH: Mood and anxiety fluctuation in Parkinson's disease associated with levodopa infusion: Preliminary findings. Movement Disord (1995) 10(3):329-332.
75. Chen JJ, Obering C: A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease. Clin Ther (2005) 27(11):1710- 1724.
76. 1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol (2005) 57(1):17-26.
77. Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, Romashko D, Scott R, Tully T: A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA (2003) 100(18):10518-10522.
78. Wood MA, Kaplan MP, Park A, Blanchard EJ, Oliveira AM, Lombardi TL, Abel T: Transgenic mice expressing a truncated form of CREB-binding protein (CBP) exhibit deficits in hippocampal synaptic plasticity and memory storage. Learn Mem (2005) 12(2):111-119.
79. Colombo PJ, Brightwell JJ, Countryman RA: Cognitive strategy-specific increases in phosphorylated cAMP response element-binding protein and c-Fos in the hippocampus and dorsal striatum. J Neurosci (2003) 23(8):3547-3554.
80. Chalovich EM, Zhu JH, Caltagarone J, Bowser R, Chu CT: Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells. J Biol Chem (2006) 281(26):17870-17881.
81. +. J Neural Transm Suppl (1995) 46:217-228.
82. Yang L, Calingasan NY, Lorenzo BJ, Beal MF: Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol (2008) 211(1):311-314.
83. 2 receptors.
84. Zhang HT, Huang Y, Masood A, Stolinski LR, Li Y, Zhang L, Dlaboga D, Jin SL, Conti M, O'Donnell JM: Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). Neuropsychopharmacology (2008) 33(7):1611-1623.
85. Chalimoniuk M, Langfort J, Lukacova N, Marsala J: Upregulation of guanylyl cyclase expression and activity in striatum of MPTP-induced parkinsonism in mice. Biochem Biophys Res Commun (2004) 324(1):118-126.
86. Kakkar R, Raju RV, Rajput AH, Sharma RK: Amantadine: An antiparkinsonian agent inhibits bovine brain 60 kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res (1997) 749(2):290-294.
87. Furuyama T, Iwahashi Y, Tano Y, Takagi H, Inagaki S: Localization of 63-kDa calmodulin-stimulated phosphodiesterase mRNA in the rat brain by in situ hybridization histochemistry. Brain Res Mol Brain Res (1994) 26(1-2):331-336.
88. Fujishige K, Kotera J, Michibata H, Yuasa K, Takebayashi S, Okumura K, Omori K: Cloning and characterization of a novel human phosphodiesterase that hydrolyzes both cAMP and cGMP (PDE10A). J Biol Chem (1999) 274(26):18438-18445.
89. 2+. J Neurochem (1992) 59(6):2024-2029.
90. Polli JW, Kincaid RL: Expression of a calmodulin-dependent phosphodiesterase isoform (PDE1B1) correlates with brain regions having extensive dopaminergic innervation. J Neurosci (1994) 14(3 Pt 1):1251-1261.
91. -/- mice suggests that these striatal PDEs are involved in the regulation of distinct intracellular signaling pathways, despite both being striatal PDEs.
92. -/- mice also displayed behavioral deficits in tasks dependent on locomotor or visual acuity, and demonstrated reduced performance location of the platform in the Morris water maze, which is indicative of spatial learning deficits.
93. Shibuya M: Dopamine-sensitive adenylate cyclase activity in the striatum in Parkinson's disease. J Neural Transm (1979) 44(4):287-295.
94. Pickering M, O'Connor JJ: Pro-inflammatory cytokines and their effects in the dentate gyrus. In: Progress in Brain Research: The Dentate Gyrus: A Comprehensive Guide to Structure, Function, and Clinical Implications. Scharfman HE (Ed), Elsevier BV, Amsterdam, The Netherlands (2007) 163:339-354.
95. Block ML, Hong, JS: Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans (2007) 35(5):1127-1132.
96. Kadiu I, Glanzer JG, Kipnis J, Gendelman HE, Thomas MP: Mononuclear phagocytes in the pathogenesis of neurodegenerative diseases. Neurotox Res (2005) 8(1-2):25-50.
97. Dheen ST, Kaur C, Ling EA: Microglial activation and its implications in the brain diseases. Curr Med Chem (2007) 14(11):1189-1197.
98. Mosley RL, Benner EJ, Kadiu I, Thomas M, Boska MD, Hasan K, Laurie C, Gendelman HE: Neuroinflammation, oxidative stress and the pathogenesis of Parkinson's disease. Clin Neurosci Res (2006) 6(5):261-281.
99. Reenilä I, Tuomainen P, Soinila S, Männistö PT: Increase of catechol-O-methyltransferase activity in rat brain microglia after intrastriatal infusion of fluorocitrate, a glial toxin. Neurosci Lett (1997) 230(3):155-158.
100. Katsarou Z, Bostantjopoulou S, Hatzizisi O, Giza E, Soler-Cardona A, Kyriazis G: Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev Neurol (2007) 45(12):725-728.
101. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T: Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord (2005) 11(8):493-498.
102. Orr CF, Rowe DB, Mizuno Y, Mori H, Halliday GM: A possible role for humoral immunity in the pathogenesis of Parkinson's disease. Brain (2005) 128(11):2665-2674.
103. Keshet GI, Tolwani RJ, Trejo A, Kraft P, Doyonnas R, Clayberger C, Weimann JM, Blau HM: Increased host neuronal survival and motor function in BMT parkinsonian mice: Involvement of immunosuppression. J Comp Neurol (2007) 504(6):690-701.
104. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL: Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J Leukocyte Biol (2007) 2(5):1083- 1094.
105. Qian L, Hong JS, Flood PM: Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: Neuroprotective effect of interleukin 10. J Neural Transm Suppl (2006) 70:367-371.
106. Wong AH, Van Tol HH: Schizophrenia: From phenomenology to neurobiology. Neurosci Biobehav Rev (2003) 27(3):269-306.
107. Pallanti S, Quercioli L, Pazzagli A: Effects of clozapine on awareness of illness and cognition in schizophrenia. Psychiatry Res (1999) 86(3):239-249.
108. Howard AK, Thornton AE, Altman S, Honer WG: Donepezil for memory dysfunction in schizophrenia. J Psychopharmacol (2002) 16(3):267-270.
109. Meltzer HY, McGurk SR: The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull (1999) 25(2):233-255.
110. Rosengarten H, Quartermain D: Effect of prenatal administration of haloperidol, risperidone, quetiapine and olanzapine on spatial learning and retention in adult rats. Pharmacol Biochem Behav (2002) 72(3):575-579.
111. Munn NA: Microglia dysfunction in schizophrenia: An integrative theory. Med Hypotheses (2000) 54(2):198-202.
112. Meyer U, Feldon J, Schedlowski M, Yee BK: Towards an immuno-precipitated neurodevelopmental animal model of schizophrenia. Neurosci Biobehav Rev (2005) 29(6):913-947.
113. Smith SE, Li J, Garbett K, Mirnics K, Patterson PH: Maternal immune activation alters fetal brain development through interleukin-6. J Neurosci (2007) 27(40):10695-10702.
114. Zalcman S, Savina I, Wise RA: Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res (1999) 847(2):276-283.
115. Nawa H, Takei N: Recent progress in animal modeling of immune inflammatory processes in schizophrenia: Implication of specific cytokines. Neurosci Res (2006) 56(1):2-13.
116. Ganguli R, Brar JS, Chengappa KN, Yang ZW, Nimgaonkar VL, Rabin BS: Autoimmunity in schizophrenia: A review of recent findings. Ann Med (1993) 25(5):489-496.
117. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: A systematic quantitative review. Biol Psychiatry (2008) 63(8):801-808.
118. Bayer TA, Buslei R, Havas L, Falkai P: Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett (1999) 271(2):126-128.
119. Hanson DR, Gottesman II: Theories of schizophrenia: A genetic-inflammatory-vascular synthesis. BMC Med Genet (2005) 6:7.
120. Yao YK, van Kammen DP: Membrane phospholipids and cytokine interaction in schizophrenia. In: International Review of Neurobiology: Disorders of Synaptic Plasticity and Schizophrenia. Smythies J (Ed), Elsevier BV, Amsterdam, The Netherlands (2004) 59:297-326.
121. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K: Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry (2007) 62(7):711-721.
122. Saetre P, Emilsson L, Axelsson E, Kreuger J, Lindholm E, Jazin E: Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry (2007) 7:46.
123. Wassink TH, Crowe RR, Andreasen NC: Tumor necrosis factor receptor-II: Heritability and effect on brain morphology in schizophrenia. Mol Psychiatry (2000) 5(6):678-682.
124. Müller N, Schwarz MJ: Immunology in schizophrenic disorders. Nervenarzt (2007) 78(3):253-263.
125. Smith RS, Maes M: The macrophage-T-lymphocyte theory of schizophrenia: Additional evidence. Med Hypotheses (1995) 45(2):135-141.
126. Müller N, Ackenheil M: Psychoneuroimmunology and the cytokine action in the CNS: Implications for psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry (1998) 22(1):1-33.
127. De Keyser J, Mostert JP, Koch MW: Dysfunctional astrocytes as key players in the pathogenesis of central nervous system disorders. J Neurol Sci (2008) 267(1-2):3-16.
128. Na KS, Kim YK: Monocytic, Th1 and Th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology (2007) 56(2-3):55-63.
129. Pae CU, Yoon CH, Kim TS, Kim JJ, Park SH, Lee CU, Lee SJ, Lee C, Paik IH: Antipsychotic treatment may alter T-helper (Th) 2 arm cytokines. Int Immunopharmacol (2006) 6(4):666-671.
130. Cazzullo CL, Trabattoni D, Saresella M, Annoni G, Arosio B, Clerici M: Research on psychoimmunology. World J Biol Psychiatry (2003) 4(3):119-123.
131. 3 receptor and schizophrenia: A widened scope for the immune hypothesis. Med Hypotheses (2006) 67(2):354-358.
132. 3 receptor stimulation in the induction of neurogenesis in the adult rat substantia nigra. Neuroscience (2005) 136(2):381-386.
133. 3 receptor stimulation. Eur J Neurosci (2004) 19(9):2377-2387.
134. Leykin I, Mayer R, Shinitzky M: Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology (1997) 37(1):75-86.
135. Halene TB, Siegel SJ: PDE inhibitors in psychiatry - Future options for dementia, depression and schizophrenia? Drug Discov Today (2007) 12(19-20):870-878.
136. Millar JK, Pickard BS, Mackie S, James R, Christie S, Buchanan SR, Malloy MP, Chubb JE, Huston E, Baillie GS, Thomson PA et al: DISC1 and PDE4B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science (2005) 310(5751):1187-1191. •• This paper reports the pioneering research that outlines the genetic mechanisms of DISC1 interaction with PDE4B in the genetic susceptibility to schizophrenia.
137. Millar JK, Mackie S, Clapcote SJ, Murdoch H, Pickard BS, Christie S, Muir WJ, Blackwood DH, Roder JC, Houslay MD, Porteous DJ: Disrupted in schizophrenia 1 and phosphodiesterase 4B: Towards an understanding of psychiatric illness. J Physiol (2007) 584(2):401-405. •• Under normal conditions, DISC1 interacts with PDE4B and PDE4B dissociates from DISC1 following increased cellular cAMP levels. Mutations in the DISC1 gene prevent PDE4B binding, while PDE4B mutations result in isoforms that are incompatible with DISC1 regulation. Chromosomal translocation of the PDE4 gene in a patient with schizophrenia resulted in a 50% reduction in PDE4B1 levels and, consequently, increased cellular cAMP levels augmented PDE activity. DISC1 is involved in cAMP signaling and neuronal migration. Disruptions in DISC1 and PDE4B result in alterations in brain development, effect and cognition. The abrogated regulation of cAMP signaling may be directly linked to learning, memory and mood alterations in individuals with clinical depression and schizophrenia.
138. Pickard BS, Thomson PA, Christoforou A, Evans KL, Morris SW, Porteous DJ, Blackwood DH, Muir WJ: The PDE4B gene confers sex-specific protection against schizophrenia. Psychiatr Genet (2007) 17(3):129-133.
139. Kanes SJ, Tokarczyk J, Siegel SJ, Bilker W, Abel T, Kelly MP: Rolipram: A specific phosphodiesterase 4 inhibitor with potential antipsychotic activity. Neuroscience (2007) 144(1):239-246.
140. Polesskaya OO, Smith RF, Fryxell KJ: Chronic nicotine doses downregulate PDE4 isoforms that are targets of antidepressants in adolescent female rats. Biol Psychiatry (2007) 61(1):56-64.
141. Murdoch H, Mackie S, Collins DM, Hill EV, Bolger GB, Klussmann E, Porteous DJ, Millar JK, Houslay MD: Isoform-selective susceptibility of DISC1/phosphodiesterase-4 complexes to dissociation by elevated intracellular cAMP levels. J Neurosci (2007) 27(35):9513-9524.
142. Clapcote SJ, Lipina TV, Millar JK, Mackie S, Christie S, Ogawa F, Lerch JP, Trimble K, Uchiyama M, Sakuraba Y, Kaneda H et al: Behavioral phenotypes of DISC1 missense mutations in mice. Neuron (2007) 54(3):387-402.
143. Sawamura N, Sawa A: Disrupted-in-schizophrenia-1 ( DISC1): A key susceptibility factor for major mental illnesses. Ann NY Acad Sci (2006) 1086:126-133.
144. Hebb AL, Robertson HA, Denovan-Wright EM: Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms. Neuroscience (2004) 123(4):967-981. • In transgenic mouse models of Huntington's disease that express exon 1 of mutant huntingtin, PDE10A2 mRNA and protein levels decreased prior to the onset of motor symptoms and reached a minimum, corresponding to the appearance of marked motor impairments. In humans, PDE10A protein levels from the caudate, putamen and nucleus accumbens are diminished in Huntington's disease patients with severe striatal atrophy compared with neurological control individuals.
145. Hebb AL, Robertson HA: Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol (2007) 7(1):86-92.
146. Hebb AL, Robertson HA, Denovan-Wright EM: Phosphodiesterase 10A inhibition is associated with locomotor and cognitive deficits and increased anxiety in mice. Eur Neuropsychopharmacol (2008) 18(5):339- 363.
147. Menniti FS, Chappie TA, Humphrey JM, Schmidt CJ: Phosphodiesterase 10A inhibitors: A novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs (2007) 8(1):54-59.
148. Rodefer JS, Murphy ER, Baxter MG: PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci (2005) 21(4):1070-1076. • In an animal model of schizophrenia, treatment with papaverine improved attention and working memory.